Exact Mass: 566.2438
Exact Mass Matches: 566.2438
Found 500 metabolites which its exact mass value is equals to given mass value 566.2438
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Canescein
Canescein is isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the US
(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
PA(2:0/6 keto-PGF1alpha)
PA(2:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/6 keto-PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(6 keto-PGF1alpha/2:0)
PA(6 keto-PGF1alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/2:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/TXB2)
PA(2:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/TXB2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(TXB2/2:0)
PA(TXB2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/2:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(3S,5S,10S,13R,14S,17R)-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-3-[(2R,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde
(1R,2S,4S,5S,6R,7S,8S,9R,10S)-1-acetoxy-9-benzoyloxy-8-trans-cinnamoyloxy-2,4,6-trihydroxydihydro-beta-agarofuran
(2R,3S,4S)-2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-4-[(4-hydroxy-3-methoxyphenyl)methyl]tetrahydrofuran 3-{[(2R)-2-carbomethoxy-2-hydroxy]ethyl}benzoate|hyosmin
(l(-)-tyrosyl)=>glutaminyl=>glutaminyl=>-glutamic acid|(l(-)-Tyrosyl)=>glutaminyl=>glutaminyl=>-glutaminsaeure
3beta-(beta-D-glucopyranosyloxy)-19-carboxy-14beta-hydroxycard-20(22)-enolide
12-O-butenoyl-5-hydroxy-6,7-epoxy-resiniferonol-9,13,14-orthobenzoate
(2E)-1-{2,4-dihydroxy-6-methoxy-3-[(2R,4S,6S)-tetrahydro-2-(4-hydroxyphenyl)-6-(2-phenylethyl)-2H-pyran-4-yl]phenyl}-3-(4-hydroxyphenyl)prop-2-en-1-one|Katsumain D
(2E)-1-{(2R,4S)-3,4-dihydro-5-hydroxy-4-[(2S)-2-hydroxy-4-(4-hydroxyphenyl)butyl]-2-(4-hydroxyphenyl)-7-methoxy-2H-1-benzopyran-6-yl}-3-phenylprop-2-en-1-one|katsumain E
(2E)-1-{(2R,4S)-3,4-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4-[(2S)-2-hydroxy-4-phenylbutyl]-7-methoxy-2H-1-benzopyran-6-yl}-3-(4-hydroxyphenyl)prop-2-en-1-one|katsumain G
(+)-lyoniresinol-3alpha-O-alpha-L-rhamonopyranoside
(aS)-(5R,6S,7R,8R)-8-benozyloxy-5,6,7,8-tetrahydro-1,5-dihydroxy-3,12-dihydroxy-1,2,10,11-tetramethoxy-6,7-dimethyldibenzo[a,c]cycloocten-5-yl acetate|kadsuphilin I
(20S,22S,23S,24S,25S,26S)-5alpha-chloro-12alpha,22-23,26,24,25-triepoxy-12-ethoxy-6beta,17beta,26-trihydroxyergosta-2-en-1-one|12-O-ethyl-jaborosalactol 25|12-O-ethyljaborosalactol 25
Asn Tyr Arg Asp
Asn Tyr Asp Arg
4-[4-(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy-2-methoxy-3,5,6-trimethylbenzoyl]oxy-2-methoxy-3,5,6-trimethylbenzoic acid
3-[[6-[[1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid
(8xi,11alpha,14xi,17alpha)-3-[(6-Deoxyhexopyranosyl)oxy]-5,11,14-trihydroxy-19-oxocard-20(22)-enolide
Origin: Plant, Cardanolides
3-[[6-[[1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid_major
Ala Gln Trp Tyr
Ala Gln Tyr Trp
Ala Trp Gln Tyr
Ala Trp Tyr Gln
Ala Tyr Gln Trp
Ala Tyr Trp Gln
Cys Cys Arg Trp
Cys Cys Trp Arg
Cys Lys Met Trp
Cys Lys Trp Met
Cys Met Lys Trp
Cys Met Trp Lys
Cys Arg Cys Trp
Cys Arg Trp Cys
Cys Trp Cys Arg
Cys Trp Lys Met
Cys Trp Met Lys
Cys Trp Arg Cys
Asp Asn Arg Tyr
Asp Asn Tyr Arg
Asp Arg Asn Tyr
Asp Arg Tyr Asn
Asp Tyr Asn Arg
Asp Tyr Arg Asn
Glu Lys Gln Tyr
Glu Lys Tyr Gln
Glu Gln Lys Tyr
Glu Gln Gln Tyr
Glu Gln Tyr Lys
Glu Gln Tyr Gln
Glu Tyr Lys Gln
Glu Tyr Gln Lys
Glu Tyr Gln Gln
Phe His Thr Tyr
Phe His Tyr Thr
Phe Met Asn Arg
Phe Met Arg Asn
Phe Asn Met Arg
Phe Asn Arg Met
Phe Asn Thr Trp
Phe Asn Trp Thr
Phe Gln Ser Trp
Phe Gln Trp Ser
Phe Arg Met Asn
Phe Arg Asn Met
Phe Ser Gln Trp
Phe Ser Trp Gln
Phe Thr His Tyr
Phe Thr Asn Trp
Phe Thr Trp Asn
Phe Thr Tyr His
Phe Trp Asn Thr
Phe Trp Gln Ser
Phe Trp Ser Gln
Phe Trp Thr Asn
Phe Tyr His Thr
Phe Tyr Thr His
His Phe Thr Tyr
His Phe Tyr Thr
His His His His
His Pro Gln Trp
His Pro Trp Gln
His Gln Pro Trp
His Gln Trp Pro
His Thr Phe Tyr
His Thr Tyr Phe
His Trp Pro Gln
His Trp Gln Pro
His Tyr Phe Thr
His Tyr Thr Phe
Lys Cys Met Trp
Lys Cys Trp Met
Lys Glu Gln Tyr
Lys Glu Tyr Gln
Lys Met Cys Trp
Lys Met Trp Cys
Lys Gln Glu Tyr
Lys Gln Tyr Glu
Lys Trp Cys Met
Lys Trp Met Cys
Lys Tyr Glu Gln
Lys Tyr Gln Glu
Met Cys Lys Trp
Met Cys Trp Lys
Met Phe Asn Arg
Met Phe Arg Asn
Met Lys Cys Trp
Met Lys Trp Cys
Met Asn Phe Arg
Met Asn Arg Phe
Met Arg Phe Asn
Met Arg Asn Phe
Met Trp Cys Lys
Met Trp Lys Cys
Asn Asp Arg Tyr
Asn Asp Tyr Arg
Asn Phe Met Arg
Asn Phe Arg Met
Asn Phe Thr Trp
Asn Phe Trp Thr
Asn Met Phe Arg
Asn Met Arg Phe
Asn Arg Asp Tyr
Asn Arg Phe Met
Asn Arg Met Phe
Asn Arg Tyr Asp
Asn Thr Phe Trp
Asn Thr Trp Phe
Asn Trp Phe Thr
Asn Trp Thr Phe
Pro His Gln Trp
Pro His Trp Gln
Pro Gln His Trp
Pro Gln Trp His
Pro Trp His Gln
Pro Trp Gln His
Gln Ala Trp Tyr
Gln Ala Tyr Trp
Gln Glu Lys Tyr
Gln Glu Gln Tyr
Gln Glu Tyr Lys
Gln Glu Tyr Gln
Gln Phe Ser Trp
Gln Phe Trp Ser
Gln His Pro Trp
Gln His Trp Pro
Gln Lys Glu Tyr
Gln Lys Tyr Glu
Gln Pro His Trp
Gln Pro Trp His
Gln Gln Glu Tyr
Gln Gln Tyr Glu
Gln Ser Phe Trp
Gln Ser Trp Phe
Gln Trp Ala Tyr
Gln Trp Phe Ser
Gln Trp His Pro
Gln Trp Pro His
Gln Trp Ser Phe
Gln Trp Tyr Ala
Gln Tyr Ala Trp
Gln Tyr Glu Lys
Gln Tyr Glu Gln
Gln Tyr Lys Glu
Gln Tyr Gln Glu
Gln Tyr Trp Ala
Arg Cys Cys Trp
Arg Asp Asn Tyr
Arg Asp Tyr Asn
Arg Phe Met Asn
Arg Phe Asn Met
Arg Met Phe Asn
Arg Met Asn Phe
Arg Asn Asp Tyr
Arg Asn Phe Met
Arg Asn Met Phe
Arg Asn Tyr Asp
Arg Tyr Asp Asn
Arg Tyr Asn Asp
Ser Phe Gln Trp
Ser Phe Trp Gln
Ser Gln Phe Trp
Ser Gln Trp Phe
Ser Trp Phe Gln
Ser Trp Gln Phe
Thr Phe His Tyr
Thr Phe Asn Trp
Thr Phe Trp Asn
Thr Phe Tyr His
Thr His Phe Tyr
Thr His Tyr Phe
Thr Asn Phe Trp
Thr Asn Trp Phe
Thr Trp Phe Asn
Thr Trp Asn Phe
Thr Tyr Phe His
Thr Tyr His Phe
Trp Ala Gln Tyr
Trp Ala Tyr Gln
Trp Cys Lys Met
Trp Cys Met Lys
Trp Phe Asn Thr
Trp Phe Gln Ser
Trp Phe Ser Gln
Trp Phe Thr Asn
Trp His Pro Gln
Trp His Gln Pro
Trp Lys Cys Met
Trp Lys Met Cys
Trp Met Cys Lys
Trp Met Lys Cys
Trp Asn Phe Thr
Trp Asn Thr Phe
Trp Pro His Gln
Trp Pro Gln His
Trp Gln Ala Tyr
Trp Gln Phe Ser
Trp Gln His Pro
Trp Gln Pro His
Trp Gln Ser Phe
Trp Gln Tyr Ala
Trp Ser Phe Gln
Trp Ser Gln Phe
Trp Thr Phe Asn
Trp Thr Asn Phe
Trp Tyr Ala Gln
Trp Tyr Gln Ala
Tyr Ala Gln Trp
Tyr Ala Trp Gln
Tyr Asp Asn Arg
Tyr Asp Arg Asn
Tyr Glu Lys Gln
Tyr Glu Gln Lys
Tyr Glu Gln Gln
Tyr Phe His Thr
Tyr Phe Thr His
Tyr His Phe Thr
Tyr His Thr Phe
Tyr Lys Glu Gln
Tyr Lys Gln Glu
Tyr Asn Asp Arg
Tyr Asn Arg Asp
Tyr Gln Ala Trp
Tyr Gln Glu Lys
Tyr Gln Glu Gln
Tyr Gln Lys Glu
Tyr Gln Gln Glu
Tyr Gln Trp Ala
Tyr Arg Asp Asn
Tyr Arg Asn Asp
Tyr Thr Phe His
Tyr Thr His Phe
Tyr Trp Ala Gln
Tyr Trp Gln Ala
Cediranib maleate
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents
2-[(1E,3E)-5-(3,3-DIMETHYL-1-PROPYL-1,3-DIHYDRO-2H-INDOL-2-YLIDENE)-1,3-PENTADIENYL]-3,3-DIMETHYL-1-PROPYL-3H-INDOLIUM IODIDE
8H-7,10-Methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-diMethylethyl)-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-14-Methoxy-3,6-dioxo-, Methyl ester, (1aR,5S,8S,10R,18E,22aR)-
ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride
(2R)-1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,(2R)-1-(3H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,dihydrochloride
3beta-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-5,11alpha,14-trihydroxy-19-oxo-5beta-card-20(22)-enolide
(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively. D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Meclorisone dibutyrate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
Cyclopropyl-[5-[[4-[[4-(2-methoxyphenyl)-1-piperazinyl]-oxomethyl]-1-piperidinyl]sulfonyl]-2-methyl-2,3-dihydroindol-1-yl]methanone
(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-2-carboxylatoethyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoate
N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-cyanobenzamide
1-(3-methoxyphenyl)-3-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-methylbenzenesulfonamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-phenylmethanesulfonamide
1-(2-fluorophenyl)-3-[(4R,7R,8S)-5-[(2-fluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
leukotriene F4(2-)
A leukotriene anion obtained by deprotonation of the three carboxy groups and protonation of the glutamyl alpha-amino group of leukotriene F4; major species at pH 7.3.
({20-chloro-13,19,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl}oxy)methanimidic acid
(4r,5r)-1,5-bis(3,4-dimethoxyphenyl)-5-methoxy-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pentan-1-one
(1r,3as,3br,5as,7s,9as,9bs,11r,11as)-3a,5a,11-trihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[(2r,3r,4r,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
1-(1r,13r)-7,7-dimethyl-18-(3-methylbut-2-en-1-yl)-8,12,20-trioxapentacyclo[11.8.0.0²,¹¹.0⁴,⁹.0¹⁴,¹⁹]henicosa-2,4(9),5,10,14,16,18-heptaen-17-yl 2-ethyl phthalate
(1z,4s,5r,14r,15s,16s,19z)-14,16-dihydroxy-15-methoxy-5,6,6,21,21-pentamethyl-3,7,18,23-tetraazaoctacyclo[16.13.0.0³,¹⁶.0⁴,⁷.0⁴,¹⁴.0⁸,¹³.0²²,³⁰.0²⁴,²⁹]hentriaconta-1(31),8,10,12,19,22(30),24,26,28-nonaene-2,17-dione
4-[(1s,3s,5s,7r,9s,10r,12s,14s,15s,17r,18s,19r,22s,23r)-9,10,17,22-tetrahydroxy-7,14-bis(hydroxymethyl)-18-methyl-4,6,11-trioxahexacyclo[12.11.0.0³,¹².0⁵,¹⁰.0¹⁵,²³.0¹⁸,²²]pentacosan-19-yl]-5h-furan-2-one
(1r,3as,3br,5as,7s,9as,9bs,11r,11as)-3a,5a,11-trihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-7-{[(2s,3r,4r,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
34,38-dimethyl-8,10,15,22,27,29-hexaoxa-34,38-diazaundecacyclo[19.11.3.3⁴,¹⁶.2³,¹⁷.0¹,²¹.0²,¹⁸.0⁴,¹⁶.0⁵,¹³.0⁷,¹¹.0²⁴,³².0²⁶,³⁰]tetraconta-5,7(11),12,19,24,26(30),31,36-octaene
(1r,2r,4r,9r,10r,13r,14s,15s,17r)-9-(furan-3-yl)-15-(2-methoxy-2-oxoethyl)-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadec-5-en-17-yl (2e)-2-methylbut-2-enoate
6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-14-phenyl-16-(prop-1-en-2-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl but-2-enoate
5'-(furan-3-yl)-8-methyl-2'-oxo-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-decahydrospiro[naphtho[1,8a-c]furan-7,3'-oxolan]-10-yl acetate
(1s,2r,3s,4r,7s,8z,10r,12s,13r,14s)-10,12,14-tris(acetyloxy)-3-hydroxy-9-(hydroxymethyl)-4,13,17-trimethyl-5-oxo-6-oxatricyclo[11.4.0.0³,⁷]heptadeca-8,16-dien-2-yl acetate
3,6,11-tris(acetyloxy)-2,8-dihydroxy-1,5,15-trimethyl-9-methylidene-14-oxo-16-oxatetracyclo[10.5.0.0²,¹⁵.0⁵,¹⁰]heptadecan-4-yl acetate
(1r,3as,3br,5as,7s,9as,9bs,11ar)-7-{[(2r,3r,4r,5r)-5-[(1r)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy}-3a,5a-dihydroxy-11a-methyl-1-(5-oxo-2h-furan-3-yl)-dodecahydro-1h-cyclopenta[a]phenanthrene-9a-carbaldehyde
(1z,19z)-14,16-dihydroxy-15-methoxy-5,6,6,21,21-pentamethyl-3,7,18,23-tetraazaoctacyclo[16.13.0.0³,¹⁶.0⁴,⁷.0⁴,¹⁴.0⁸,¹³.0²²,³⁰.0²⁴,²⁹]hentriaconta-1(31),8,10,12,19,22(30),24,26,28-nonaene-2,17-dione
(3r)-3,8-dihydroxy-9-[(2r,4r,5r,6r)-5-hydroxy-4-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]-3-methyl-2,4-dihydrotetraphene-1,7,12-trione
(1's,2r,2's,3's,4'r,7's,8'z,10'r,12's,13'r,14's)-2',10',14'-tris(acetyloxy)-3'-hydroxy-4',9',13'-trimethyl-5'-oxo-6'-oxaspiro[oxirane-2,17'-tricyclo[11.4.0.0³,⁷]heptadecan]-8'-en-12'-yl acetate
antialloside
{"Ingredient_id": "HBIN016302","Ingredient_name": "antialloside","Alias": "NA","Ingredient_formula": "C29H42O11","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C4CC(C5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O","Ingredient_weight": "566.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1374","TCMSP_id": "NA","TCM_ID_id": "6743;21611","PubChem_id": "56841093","DrugBank_id": "NA"}
β-antiarin
{"Ingredient_id": "HBIN017975","Ingredient_name": "\u03b2-antiarin","Alias": "NA","Ingredient_formula": "C29H42O11","Ingredient_Smile": "CC1C(C(C(C(O1)OC2CCC3(C4CC(C5(C(CCC5(C4CCC3(C2)O)O)C6=CC(=O)OC6)C)O)C=O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1377","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}